Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained
| Autor: | Wolinsky, Js, Comi, G, Filippi, M, Ladkani, D, Kadosh, S, Shifroni, G, Inglese, MARIA MATILDE |
|---|---|
| Přispěvatelé: | Wolinsky, J, Comi, Giancarlo, Filippi, Massimo, Ladkani, D, Kadosh, S, Shifroni, G. |
| Jazyk: | angličtina |
| Rok vydání: | 2002 |
| Předmět: |
medicine.medical_specialty
Multiple Sclerosis Relapsing-Remitting Placebo Gastroenterology law.invention Central nervous system disease Multiple Sclerosis Relapsing-Remitting Randomized controlled trial Double-Blind Method law Internal medicine medicine Humans Glatiramer acetate Cross-Over Studies medicine.diagnostic_test business.industry Multiple sclerosis Magnetic resonance imaging Glatiramer Acetate medicine.disease Crossover study Magnetic Resonance Imaging Surgery Clinical trial Peptides Neurology (clinical) business medicine.drug |
| Popis: | All but 6% of the subjects with relapsing remitting MS who were randomly assigned to receive glatiramer acetate or placebo for the 9-month controlled phase of the European/Canadian MRI trial entered an open-label extension with quarterly clinical and MRI evaluations for another 9 months. There was a 54% reduction in the mean number of enhanced lesions for those converted from placebo to glatiramer acetate and an additional 24.6% reduction for those always on glatiramer acetate. Over the entire study the accumulated T2 disease burden was 34.2% less for those always on glatiramer acetate. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|